Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

Zhi Chun Ding, Lei Huang, Bruce R. Blazar, Hideo Yagita, Andrew L. Mellor, David H. Munn, Gang Zhou

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The finding that many chemotherapeutic agents have immunostimulatory effects has provided the impetus to combine chemotherapy and immunotherapy for synergistic antitumor effects. However, the critical determinants of effective antitumor immunity after chemotherapy have not been defined. Here we report that adoptive transfer of tumor-specific CD4+ T cells after chemotherapy with cyclophosphamide gave rise to polyfunctional CD4+ effector cells, which in turn intensified the inflammatory milieu and enhanced the activation of CD8+ T cells in the tumor microenvironment. Although this combined chemoimmunotherapy initially resulted in progressive regression of advanced B-cell lymphoma, its therapeutic efficacy was not durable and most mice succumbed to late relapse. Notably, relapse was associated with acquisition of a tolerized phenotype in tumor-specific CD4+ T cells, characterized by overexpression of program death-1 (PD-1). Remarkably, effective antitumor immunity was maintained and cure became prevalent when polyfunctional CD4+ effector cells were prevented from undergoing PD-1-mediated tolerization, either by antibody blockade of the PD-1-PD-L1 pathway, or targeted ablation of PD-1 in tumors-pecific CD4+ T cells. Our study suggests that tumor-reactive CD4+ T cells act as the "gatekeepers" of the host antitumor immunity in the postchemotherapy setting, thereby their functional status governs the choice between eradication versus regrowth of residual tumors.

Original languageEnglish (US)
Pages (from-to)2229-2239
Number of pages11
JournalBlood
Volume120
Issue number11
DOIs
StatePublished - Sep 13 2012

Fingerprint

Chemotherapy
T-cells
B-Cell Lymphoma
Tumors
Cells
T-Lymphocytes
Drug Therapy
Immunity
Neoplasms
Recurrence
Tumor Microenvironment
Adoptive Transfer
Residual Neoplasm
Immunotherapy
Cyclophosphamide
Ablation
Phenotype
Chemical activation
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. / Ding, Zhi Chun; Huang, Lei; Blazar, Bruce R.; Yagita, Hideo; Mellor, Andrew L.; Munn, David H.; Zhou, Gang.

In: Blood, Vol. 120, No. 11, 13.09.2012, p. 2229-2239.

Research output: Contribution to journalArticle

Ding, Zhi Chun ; Huang, Lei ; Blazar, Bruce R. ; Yagita, Hideo ; Mellor, Andrew L. ; Munn, David H. ; Zhou, Gang. / Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. In: Blood. 2012 ; Vol. 120, No. 11. pp. 2229-2239.
@article{848db211d5534be5b1dd030bdbb55f22,
title = "Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy",
abstract = "The finding that many chemotherapeutic agents have immunostimulatory effects has provided the impetus to combine chemotherapy and immunotherapy for synergistic antitumor effects. However, the critical determinants of effective antitumor immunity after chemotherapy have not been defined. Here we report that adoptive transfer of tumor-specific CD4+ T cells after chemotherapy with cyclophosphamide gave rise to polyfunctional CD4+ effector cells, which in turn intensified the inflammatory milieu and enhanced the activation of CD8+ T cells in the tumor microenvironment. Although this combined chemoimmunotherapy initially resulted in progressive regression of advanced B-cell lymphoma, its therapeutic efficacy was not durable and most mice succumbed to late relapse. Notably, relapse was associated with acquisition of a tolerized phenotype in tumor-specific CD4+ T cells, characterized by overexpression of program death-1 (PD-1). Remarkably, effective antitumor immunity was maintained and cure became prevalent when polyfunctional CD4+ effector cells were prevented from undergoing PD-1-mediated tolerization, either by antibody blockade of the PD-1-PD-L1 pathway, or targeted ablation of PD-1 in tumors-pecific CD4+ T cells. Our study suggests that tumor-reactive CD4+ T cells act as the {"}gatekeepers{"} of the host antitumor immunity in the postchemotherapy setting, thereby their functional status governs the choice between eradication versus regrowth of residual tumors.",
author = "Ding, {Zhi Chun} and Lei Huang and Blazar, {Bruce R.} and Hideo Yagita and Mellor, {Andrew L.} and Munn, {David H.} and Gang Zhou",
year = "2012",
month = "9",
day = "13",
doi = "10.1182/blood-2011-12-398321",
language = "English (US)",
volume = "120",
pages = "2229--2239",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

AU - Ding, Zhi Chun

AU - Huang, Lei

AU - Blazar, Bruce R.

AU - Yagita, Hideo

AU - Mellor, Andrew L.

AU - Munn, David H.

AU - Zhou, Gang

PY - 2012/9/13

Y1 - 2012/9/13

N2 - The finding that many chemotherapeutic agents have immunostimulatory effects has provided the impetus to combine chemotherapy and immunotherapy for synergistic antitumor effects. However, the critical determinants of effective antitumor immunity after chemotherapy have not been defined. Here we report that adoptive transfer of tumor-specific CD4+ T cells after chemotherapy with cyclophosphamide gave rise to polyfunctional CD4+ effector cells, which in turn intensified the inflammatory milieu and enhanced the activation of CD8+ T cells in the tumor microenvironment. Although this combined chemoimmunotherapy initially resulted in progressive regression of advanced B-cell lymphoma, its therapeutic efficacy was not durable and most mice succumbed to late relapse. Notably, relapse was associated with acquisition of a tolerized phenotype in tumor-specific CD4+ T cells, characterized by overexpression of program death-1 (PD-1). Remarkably, effective antitumor immunity was maintained and cure became prevalent when polyfunctional CD4+ effector cells were prevented from undergoing PD-1-mediated tolerization, either by antibody blockade of the PD-1-PD-L1 pathway, or targeted ablation of PD-1 in tumors-pecific CD4+ T cells. Our study suggests that tumor-reactive CD4+ T cells act as the "gatekeepers" of the host antitumor immunity in the postchemotherapy setting, thereby their functional status governs the choice between eradication versus regrowth of residual tumors.

AB - The finding that many chemotherapeutic agents have immunostimulatory effects has provided the impetus to combine chemotherapy and immunotherapy for synergistic antitumor effects. However, the critical determinants of effective antitumor immunity after chemotherapy have not been defined. Here we report that adoptive transfer of tumor-specific CD4+ T cells after chemotherapy with cyclophosphamide gave rise to polyfunctional CD4+ effector cells, which in turn intensified the inflammatory milieu and enhanced the activation of CD8+ T cells in the tumor microenvironment. Although this combined chemoimmunotherapy initially resulted in progressive regression of advanced B-cell lymphoma, its therapeutic efficacy was not durable and most mice succumbed to late relapse. Notably, relapse was associated with acquisition of a tolerized phenotype in tumor-specific CD4+ T cells, characterized by overexpression of program death-1 (PD-1). Remarkably, effective antitumor immunity was maintained and cure became prevalent when polyfunctional CD4+ effector cells were prevented from undergoing PD-1-mediated tolerization, either by antibody blockade of the PD-1-PD-L1 pathway, or targeted ablation of PD-1 in tumors-pecific CD4+ T cells. Our study suggests that tumor-reactive CD4+ T cells act as the "gatekeepers" of the host antitumor immunity in the postchemotherapy setting, thereby their functional status governs the choice between eradication versus regrowth of residual tumors.

UR - http://www.scopus.com/inward/record.url?scp=84866342671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866342671&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-12-398321

DO - 10.1182/blood-2011-12-398321

M3 - Article

VL - 120

SP - 2229

EP - 2239

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -